Sohomoy

What Is Driving the Aflibercept Drug Market Growth?

2 min read
0
Comments
83
Views

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat a range of ophthalmic conditions, including age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). By blocking VEGF, aflibercept reduces the growth of abnormal blood vessels in the eye, helping to preserve vision and improve patient outcomes. The market for aflibercept is expanding rapidly, driven by the rising prevalence of eye diseases, an aging population, and continuous innovation in drug formulations and delivery.

According to recent market analysis, the global Aflibercept Drug Market was valued at approximately USD 4.67 billion in 2024 and is projected to reach USD 9.24 billion by 2032, growing at a robust CAGR of 8.9%. This growth reflects both the increasing burden of retinal diseases and the pharmaceutical industry's investment in developing more effective and convenient therapies.

Rising Prevalence of Age-Related Macular Degeneration

The primary driver is the increasing prevalence of age-related macular degeneration (AMD), the leading cause of vision loss in people over 50. As the global population ages, the number of people affected by AMD is expected to grow significantly, driving demand for effective treatments like aflibercept. Additionally, the rising incidence of diabetes worldwide is fueling demand for treatments for diabetic macular edema (DME), another major indication for aflibercept.

Technological Advancements in Drug Delivery

Technological innovation is also shaping the market. The development of sustained-release formulations and longer-acting versions of aflibercept is reducing the frequency of injections, improving patient convenience and compliance. Additionally, research into combination therapies and new indications is expanding the applications of aflibercept. These innovations are driving market growth and improving outcomes for patients with retinal diseases.

People Also Ask

What is the market size of aflibercept?
The aflibercept drug market was valued at USD 4.67 billion in 2024 and is projected to reach USD 9.24 billion by 2032, growing at a CAGR of 8.9%.

What are the key indications for aflibercept?
Key indications include age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Regional dynamics further shape the market. North America leads with a significant share, supported by advanced healthcare infrastructure and high AMD prevalence. Europe follows closely, while Asia-Pacific is the fastest-growing region, driven by increasing healthcare investments and rising diabetes prevalence.

Tags: #Aflibercept #AntiVEGF #AMD #DiabeticMacularEdema #Ophthalmology